Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Cancer
Conditions: official terms
Adenoma, Islet Cell - Apudoma - Carcinoid Tumor - Neuroendocrine Tumors
Conditions: Keywords
MRI, CT, 12-058
Study Type
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Name: MRI
Type: Other
Overall Status
Sunitinib and everolimus are two new treatments approved in 2011 for patients with pancreatic neuroendocrine tumors (NETs). In addition, some traditional chemotherapies are often used to treat pancreatic NETs. Traditional chemotherapy is also known as "cytotoxic therapy" and works by killing cells that are actively dividing. There have been no studies to compare the different types of treatment. Since the patient is eligible for treatment with either sunitinib, everolimus or traditional chemotherapy it can help us identify factors that may help future patients benefit from these therapies.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Histopathologic evidence of well differentiated pancreatic NET

- Evidence of metastatic disease of at least 2.0 cm in the liver by prior MRI or CT imaging. Both patients with synchronous disease and those with prior resected primary cancers will be eligible.

- Patient ≥18 years of age on the day of signing informed consent.

- Planned initiation of active therapy with everolimus ,sunitinib or traditional cytotoxic chemotherapy.

Patients can be included in this study, regardless of prior therapy, but cannot undergo concurrent therapy, such as hepatic artery embolization

- Available archival tissue with adequate FFPE tissue for analysis verified by a pathologist (in cases of biopsies less than 2 cm and/or less than 70% tumor content 10 slides will be required for adequate DNA preparation. For larger biopsies and any resections, 5 slides are sufficient for DNA extraction).

Exclusion Criteria:

- Patient has a history of a second active malignancy with evidence of metastases. Patients with a history of resected prior malignancy are allowed.

- Patient has known psychiatric or substance abuse disorders that would, in the opinion of the treating investigator, interfere with cooperation with the requirements of the trial.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Diane Reidy-Lagunes, MD - 646-888-4185
Start Date
May 2012
Completion Date
May 2016
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page